The aim of this study is to show whether rosuvastatin influences adenosine metabolism. Therefore we will determine whether rosuvasatin increases dipyridamole-induced vasodilation by increased adenosine receptor stimulation...
Date First Received: November 5, 2007
Last Updated: September 22, 2008
Verified by: Radboud University, September 2008
Clinical Trial Phase: N/A | Start Date: November 2007
Overall Status: Completed
Estimated Enrollment: 24
Brief Summary
Official Title: “Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.”
Condition Keyword(s):
Intervention(s):
The aim of this study is to show whether rosuvastatin influences adenosine metabolism.
Therefore we will determine whether rosuvasatin increases dipyridamole-induced vasodilation by increased adenosine receptor stimulation.
Study Type: Interventional
Study Design: Basic Science, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment
Study Primary Completion Date: March 2008
Intervention(s) in this Clinical Trial
- Drug: placebo
- 1 dd for 7-10 days
- Drug: rosuvastatin
- 1 dd 20 mg for 7-10 days
Arms, Groups and Cohorts in this Clinical Trial
- Placebo Comparator: 1
- Experimental: 2
Outcome Measures for this Clinical Trial
Primary Measures
- forearm vasodilatory response to dipyridamole
- Time Frame: 7 days
- Time Frame: 7 days
Secondary Measures
- lipid profile
- Time Frame: 7-10 days
- Time Frame: 7-10 days
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- age 18 - 50 years
- Signed informed consent
Exclusion Criteria:
- hypertension
- hypercholesterolemia
- diabetes Mellitus
- alanine aminotransferase > 90 U/L
- creatinine Kinase > 440 U/L
- cardiovascular disease
- GFR < 80 ml/min
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 50 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: Radboud University
Overall Clinical Trial Officials and Contacts
Gerard Rongen, MD, PhD Study Director Radboud University Medical Centre Dep. Pharmacology-Toxicology
Additional Information
Information obtained from ClinicalTrials.gov on October 10, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00554138
Study ID Number: Rosudip01
ClinicalTrials.gov Identifier: NCT00554138
Health Authority: Netherlands: Medical Ethics Review Committee (METC)
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
